or in combination with other antiplatelet agents, in patients at a risk of cardiovascular events, such as myocardial infarction and cerebrovascular accident.
Aspirin causes topical injury of the gastrointestinal mucosa and systemic depletion of mucosal prostaglandins due to COX inhibition. 1 Most gastrointestinal mucosal damages during low-dose ASA use for heart protection are asymptomatic. 5 Nevertheless, low-dose ASA use is significantly associated with gastrointestinal bleeding (GIB) complications. Peptic ulcer bleeding is the most frequently observed type of upper gastrointestinal bleeding (UGIB) in ASA users. Concomitant use of proton pump inhibitors (PPIs) and ASA effectively reduced the risk of ASA-related UGIB. 6 Moreover, increasing evidence has demonstrated that ASA users are at a risk of lower gastrointestinal bleeding (LGIB). [7] [8] [9] With rapid ageing of populations and increasing low-dose ASA use, the incidence of low-dose ASA-related LGIB is expected to increase in the future. However, the risk of low-dose ASA-related LGIB has rarely been investigated on a large scale. Therefore, we conducted a nationwide study to evaluate the risk of LGIB in low-dose ASA users. Furthermore, we examined the risk factors for low-dose ASA-related LGIB.
| MATERIALS AND METHODS

| Study design
The National Health Insurance Research Database (NHIRD) of Taiwan contains the detailed health care data of more than 23 million enrollees (more than 99% of the Taiwanese population). We compared low-dose ASA users with controls matched by age, gender, and enrollment time in a 1:5 ratio. This cohort was selected from 1 million randomly sampled subjects from the NHIRD and was representative of the whole Taiwanese population. Diagnosis was based on International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes, which were validated in a previous study by Lanas et al. with an accuracy rate of approximately 95%. 10 The inclusion criteria were as followed: (1) 
| Definitions
Comorbidities were identified according to the receipt of an ICD-9-CM code once for hospitalisation and emergency room claims or three times for out-patient claims before enrollment in the study.
The comorbidities included coronary artery disease (ICD-9-CM 
| RESULTS
A total of 53 805 low-dose ASA users and 269 025 controls were included in this study ( Figure 1 ). Tables 1 and 2 present the baseline characteristics of the two groups. The numbers of patients in the low-dose ASA group who experienced ischaemic stroke and used NSAIDs, COX-2 inhibitors, steroids, SSRIs, alendronate, PPIs, H2RAs, nitrates, calcium channel blockers, warfarin, ticlopidine and clopidogrel were higher than those in the control group.
| Incidence and risk factors for LGIB in the whole population
The low-dose ASA group had a significantly higher incidence of LGIB PPIs and H2RAs were significantly associated with LGIB (Table 3) .
| Incidence and risk factors for LGIB in patients aged ≥75 years
For patients aged ≥75 years, the low-dose ASA group had a significantly higher incidence of LGIB within 1 year than the control group (1.37% vs 0.29%, P =.0013) ( Figure 3 After adjustments for significant univariate independent predictors, only low-dose ASA was significantly associated with LGIB (Table 4 ).
| Incidence and risk factors for LGIB in patients aged <75 years
For patients aged <75 years, the low-dose ASA group had a significantly higher incidence of LGIB within 1 year than the control group LGIB. After adjustments for significant variables of univariate independent predictors, low-dose ASA, NSAIDs, steroids, SSRIs, PPIs and
H2RAs were significantly associated with LGIB (Table 5 ).
| DISCUSSION
According to our review of the relevant literature, our nationwide cohort is the largest used in a study specifically evaluating the risk of LGIB in low-dose ASA users. We observed that low-dose ASA use was associated with an increased incidence of LGIB. NSAIDs, steroids, SSRIs, PPIs and H2RAs were independent risk factors for
LGIB. Our study provides evidence on the risk of low-dose ASArelated LGIB. Although the risk is low, the present findings may facilitate the management of low-dose ASA users.
The incidence of LGIB within 1 year in low-dose ASA users was 0.20% in our study; this result is consistent with a previous study on NSAIDs/ASA-related LGIB. 8 LGIB than the use of NSAIDs alone. 13 Our results imply that LGIB symptoms should be closely monitored in low-dose ASA users receiving NSAIDs.
Several studies have reported conflicting results on the association between steroid use and GIB. A meta-analysis revealed that the risk of GIB is not increased in patients using steroids. Nevertheless, a recent large meta-analysis revealed that steroid use is associated with an increased risk of GIB. 16 Furthermore, steroids increased the risk of UGIB in low-dose ASA users. 17 Steroids were associated with
LGIB in our study. Although the mechanism underlying steroidsrelated LGIB is not well defined, steroids may impair the process for repairing preexisting lower gastrointestinal lesions, thus increasing the risk of LGIB. Follow-up (month) Patients at risk 6 7 8 9 10 11 12 Cumulative hazard for lower gastrointestinal bleeding F I G U R E 2 Cumulative hazard for lower gastrointestinal bleeding in low-dose aspirin users and matched controls. Low-dose aspirin users had a significantly higher incidence of lower gastrointestinal bleeding within 1 year than matched controls T A B L E 3 Multi-variate independent predictors for lower gastrointestinal bleeding in low-dose aspirin users and matched controls
Variables
Hazard ratio 95% Confidence interval P value NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; PPIs, proton pump inhibitors; H2RAs, histamine-2 receptor antagonists. This table displays results of multi-variate analysis after adjustments for significant univariate independent predictors for lower gastrointestinal bleeding in low-dose aspirin users and matched controls.
The antiplatelet properties of SSRIs have been well demonstrated. 18 A study on patients with congestive heart failure revealed that SSRIs provide additional antiplatelet protection in patients receiving ASA. 19 However, several studies have showed that patients using SSRIs are at an increased risk of GIB. 20, 21 Concomitant use of SSRIs and ASA has been reported to further increase the risk of UGIB. 22, 23 We observed that the concomitant use of SSRIs in lowdose ASA users is associated with an increased risk of LGIB, which may be due to the enhanced antiplatelet properties that cause bleeding of the pre-existing lower gastrointestinal lesions, similar to that observed after using low-dose ASA alone.
Nitrovasodilators have been associated with a decreased risk of UGIB in patients taking NSAIDs. 24, 25 However, a subsequent study did not identify nitrates as a protective factor against UGIB in lowdose ASA users. 26 Although nitrates were significantly associated with LGIB in univariate analysis in our study, the association was not significant in multi-variate analysis. Therefore, the effects of nitrates on the risk of LGIB in low-dose ASA users are yet to be clarified.
Anti-secretory drugs are typically associated with a decreased risk of UGIB in ASA users. 25 However, these drugs do not exert protective effects on the lower gastrointestinal tract. Gastroprotective agents, including PPIs and H2RAs, were unexpectedly found to be associated with LGIB in our cohort. In a Japanese study on patients receiving low-dose ASA, PPIs and H2RAs were risk factors for GIB in univariate analysis. 27 Another study comparing ASA users and controls reported an increased risk of UGIB in patients with a history Low-dose aspirin users:
Matched controls:
Patients at risk Cumulative hazard for lower gastrointestinal bleeding F I G U R E 3 Cumulative hazard for lower gastrointestinal bleeding in low-dose aspirin users and matched controls aged ≥75 years. Low-dose aspirin users aged ≥75 years had a significantly higher incidence of lower gastrointestinal bleeding within 1 year than matched controls of PPI use and a current or past history of H2RA use. 28 Increased
LGIB risk was observed in ASA users receiving PPIs. 8, 29, 30 PPIs are considered as an indicator of poor comorbidity status. 31 These patients remained at a risk of LGIB even after PPI or H2RA use.
Our study has several limitations. First, the observation period was 1 year; therefore, the study results may not be applicable to long-term low-dose ASA users. Second, detailed patient information
were not available because of the inherent limitations of the NHIRD.
Patient compliance was not examined, and the effects of medications, including low-dose ASA, on LGIB should be interpreted cautiously. Third, the use of over-the-counter medications was not evaluated in this study; consequently, the actual risk of low-dose ASA-related LGIB might have been overestimated. Fourth, more patients in the low-dose ASA group experienced ischaemic stroke and used pro-bleeding drugs. Patients using antiplatelet drugs are more likely to have comorbidities and use pro-bleeding drugs. 34 However, low-dose ASA remained an independent risk factor for NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; PPIs, proton pump inhibitors; H2RAs, histamine-2 receptor antagonists. This table displays results of multi-variate analysis after adjustments for significant univariate independent predictors for lower gastrointestinal bleeding in low-dose aspirin users and matched controls aged <75 years.
LGIB after adjustments for age, gender, comorbidities and pro-bleeding drugs. Finally, ICD-9-CM was used in the NHIRD during the study period. Studies using 10th Revision of International Classification of Diseases are warranted to evaluate the risk of LGIB in longterm low-dose ASA users.
In conclusion, the risk of LGIB was higher in low-dose ASA users than in ASA nonusers in this nationwide cohort. Low-dose ASA, NSAIDs, steroids, SSRIs, PPIs, and H2RAs were independent risk factors for LGIB. Patients requiring antiplatelet therapy should be informed about the risk of LGIB before low-dose ASA use, and a strategy should be developed to prevent and monitor LGIB in lowdose ASA users.
